Aspergillosis is an infection caused by Aspergillus, a common mold (a type of fungus) that breeds indoors and outdoors. Most people breathe in Aspergillus spores every day without getting sick. However, people with a weak immune system or lung diseases are at a higher risk of developing health problems due to Aspergillus. Some of the health problems caused due to Aspergillus include allergic reactions, lung infections, and infections in other organs of the body. There are different types of aspergillosis including Allergic bronchopulmonary aspergillosis (ABPA), Allergic Aspergillus sinusitis, Aspergilloma, Chronic pulmonary aspergillosis, Invasive aspergillosis, and Cutaneous (skin) aspergillosis. Common sign and symptoms of aspergillosis include wheezing, shortness of breath, cough, fever, runny nose, headache, chest pain and fatigue. The drug candidates in the pipeline for the treatment of aspergillosis include, but are not limited to F 901318, T 2307 and PC 945. Companies such as Cidara Therapeutics, Inc., Scynexis, Lypro Biosciences, Inc. and Pulmatrix, Inc. having drugs in pipeline to treat aspergillosis.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licencing, grants, technology and others.